Skip to content
Calculator
Evidence: HighPeptideIn Clinical TrialsSomatostatin analogueNot FDA-approvedVariceal bleeding

Vapreotide

A somatostatin analogue for bleeding varices that never reached US approval

Vapreotide is a somatostatin analogue developed at Tulane University and licensed to Debiopharm. In a phase 3 trial in patients with cirrhosis and bleeding oesophageal varices, starting it early, before endoscopy, improved control of bleeding and survival over five days. It has no FDA approval.

Used in human trials: 50 µg bolus, then 50 µg/h, Continuous infusion, Intravenous (Trial: acute variceal bleeding in cirrhosis, before endoscopy) Details ↓

Overview

What is it?

Bleeding from oesophageal varices is a life-threatening complication of portal hypertension in cirrhosis, and recommended treatment includes giving a vasoactive drug early. Vapreotide is a somatostatin analogue with a different receptor affinity from octreotide; in rats with cirrhosis it lowered portal pressure and blood flow in collateral vessels, and it is much more metabolically stable than somatostatin itself.

Its pivotal trial gave a 50 µg intravenous bolus and then 50 µg an hour for five days, starting a mean of 2.3 hours after admission, before endoscopic treatment. At endoscopy, active bleeding was seen in 31% on vapreotide against 46% on placebo, and survival with control of bleeding over five days was 66% against 50%. Reviews also describe a meta-analysis of four randomised studies showing better bleeding control, and a mortality reduction in the subset with significant bleeding.

Like other somatostatin analogues, it was tried in cancer. In men with prostate cancer that had escaped hormone therapy, a few responded, some for years; in metastatic breast cancer, it lowered IGF-1 but no tumour shrank. As a radiolabelled imaging agent it offered nothing over octreotide. Laboratory work found an unexpected second action, blocking the NK1 receptor for substance P.

Other uses held up less well: a placebo-controlled trial in pancreatic surgery found no benefit, and the AIDS-diarrhoea data are uncontrolled. In volunteers, a week of infusion sharply reduced gallbladder emptying. Despite the variceal results, an openFDA search finds no US approval.

31% vs 46%
Active bleeding at endoscopy
Vapreotide against placebo · PMID 11136956
50 µg/h
Infusion after a 50 µg bolus
Five days · PMID 11136956
Not FDA
No US approval
openFDA search
Science

Mechanism of Action

Vapreotide is a synthetic octapeptide somatostatin analogue, more stable than somatostatin, with a receptor affinity different from octreotide's.

🩸

Portal pressure

In cirrhotic rats it lowered portal pressure and collateral blood flow without systemic effects.

🛑

Somatostatin-like inhibition

Lowered IGF-1 in women with breast cancer and sharply reduced gallbladder emptying in volunteers; its rise in stomach pH faded within a week.

🧪

NK1 receptor

Also blocks substance P at the NK1 receptor in human cells, reducing inflammatory signalling.

Evidence

Published Research

Studies of vapreotide, from their PubMed abstracts.

Human2001

Early vapreotide for variceal bleeding

In 196 patients with cirrhosis, active bleeding at endoscopy was 31% on vapreotide against 46% on placebo (P = 0.03), and survival with bleeding control over 5 days was 66% against 50% (P = 0.02).

PMID: 11136956
Human2003

No benefit after pancreatectomy

In a double-blind trial of 275 patients having elective pancreatic resection, pancreas-related complications occurred in 30.4% on vapreotide and 26.4% on placebo, and other complications in 40% and 42%; neither difference was significant.

PMID: 12691930
Human1999

Gut effects in healthy volunteers

In a crossover trial in 10 healthy men, a week of continuous vapreotide (1.5 mg a day under the skin) cut meal-stimulated gallbladder ejection to 18-20% against 57-62% on placebo; its rise in gastric pH faded from day 2 to day 7, and gastrin did not change.

PMID: 10190655
Human1992

Refractory AIDS-related diarrhoea

In an open pilot study of 34 patients, 4 of 30 evaluable had a complete and 12 a partial response (stool output down by more than half) at 14 days; those without cryptosporidiosis responded more often (P = 0.013), and 5 of 8 responders relapsed.

PMID: 1354449
Human2003

Prostate cancer at relapse

In 13 men whose prostate cancer had escaped androgen ablation, vapreotide gave 2 complete and 4 partial responses by ECOG criteria, with only transient mild diarrhoea; three remained in remission beyond three years.

PMID: 12772187
Human1999

Metastatic breast cancer: no responses

In 14 women given high-dose continuous infusion, IGF-1 fell and raised prolactin normalised, but no tumour responded and all progressed within three months; abscesses formed at the infusion site in eight.

PMID: 10188884
Human1998

As an imaging agent

In four patients, indium-labelled vapreotide found the same lesions as labelled octreotide but cleared more slowly, giving higher background, and added nothing for scintigraphy.

PMID: 9473268
Review2008

The evidence base

Vapreotide, with a receptor affinity different from octreotide's, lowered portal pressure in cirrhotic rats; its pivotal trial improved bleeding control, with lower mortality in significant bleeding, and a meta-analysis of four trials improved bleeding control.

PMID: 19072353
Review2009

Benefit and side effects

Vapreotide appeared to help control acute variceal bleeding, was easy to give and had few, minor side effects; the authors called for further trials.

PMID: 19708854
Review2003

Drug profile

Vapreotide (Octastatin, Sanvar, RC 160, BMY 41606), developed at Tulane University and licensed to Debiopharm, is far more metabolically stable than somatostatin and is usually given subcutaneously, with slow-release forms in development.

PMID: 12952505
Review2000

Development programme

Debiopharm was running phase 3 trials of vapreotide in prostate cancer in France and in acute oesophageal variceal bleeding in France and Asia, and investigating acromegaly.

PMID: 16047258
Animal2003

Collateral blood flow in cirrhotic rats

A single dose lowered collateral (splenorenal shunt) blood flow by 17% and portal pressure by 8% without systemic effects; chronic dosing slowed the development of collateral flow.

PMID: 12645803
In Vitro2013

A second target: the NK1 receptor

In human cells, vapreotide blocked substance P signalling through the NK1 receptor, reduced inflammatory cytokine release and inhibited HIV-1 infection of macrophages.

PMID: 23921645
Dosing

Dosing Data

There is no approved dose. The variceal bleeding trial gave a 50 µg intravenous bolus, then 50 µg an hour for five days.

Not approved in the US; doses below come from trials.
ProtocolDoseFrequencyDurationRoute
Trial: acute variceal bleeding in cirrhosis, before endoscopy Human studyPMID 1113695650 µg bolus, then 50 µg/hContinuous infusion5 daysIntravenous
Trial: healthy volunteers Human studyPMID 101906551.5 mg a dayContinuous infusion1 weekSubcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Hospital infusion
Vapreotide was given as a hospital infusion in micrograms per hour; there is no approved product to dose.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Vapreotide is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

An arithmetic example, not a recommendation: a 5 mg vial mixed with 2 mL of bacteriostatic water holds 2,500 mcg per mL, so every 10 units on a U-100 insulin syringe hold 250 mcg. 1.5 mg, the first amount in the “Trial: healthy volunteers” row (1.5 mg a day) is 60.0 units (0.600 mL). If your vial or water differ, the numbers change: use the reconstitution calculator.

Source: dose: Used in human trials, PMID 10190655 (Dosing Data below); vial and water: the calculator's default example, not a vial size we have a source for.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Vapreotide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Vapreotide stays intact once mixed.

How it is taken

As it was given in human studies: Intravenous (Continuous infusion; Trial: acute variceal bleeding in cirrhosis, before endoscopy); Subcutaneous (Continuous infusion; Trial: healthy volunteers).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Trial: acute variceal bleeding in cirrhosis, before endoscopy: 5 days; Trial: healthy volunteers: 1 week.

When effects appear: unknown; no source on this page gives a time to effect for Vapreotide. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Few side effects, usually minor; Reduced gallbladder emptying during a week of continuous infusion. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Vapreotide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

Unknown: a PubMed search for human interaction studies of Vapreotide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Vapreotide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: In Clinical Trials (No FDA approval: an openFDA Drugs@FDA search for vapreotide returned no records (October 3, 2026)). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Few side effects, usually minor
● Reduced gallbladder emptying during a week of continuous infusion

Contraindications & Cautions

No US label; it is not approved in the US.

● Not approved by FDA
Questions

Frequently Asked Questions

?What is vapreotide?

A somatostatin analogue, related to octreotide, developed mainly for acute bleeding from oesophageal varices in cirrhosis.

?Did it work?

In its pivotal trial, survival with control of bleeding over five days was 66% on vapreotide against 50% on placebo when started before endoscopy.

?Is vapreotide approved in the US?

No. An openFDA search of Drugs@FDA finds no approval.

?How is it different from octreotide?

Reviews describe it as having a different somatostatin receptor affinity from octreotide; both lower portal pressure, and octreotide is approved in the US for other uses.

?How was it given in the bleeding trial?

As an intravenous bolus followed by an infusion of 50 micrograms per hour for five days, started a mean of 2.3 hours after admission, with endoscopic treatment a mean of 2.6 hours after the infusion began.

?Was it tested for other conditions?

Yes. Debiopharm ran phase 3 trials in prostate cancer in France and investigated acromegaly, and slow-release intramuscular and other sustained-release forms were developed.

?Can I buy vapreotide?

It has no FDA approval, so anything sold under its name in the US is an unverified research chemical rather than a licensed medicine.

?Did it work against cancer?

Only occasionally. In 13 men with prostate cancer that had escaped hormone therapy, six responded, some for over three years. In 14 women with metastatic breast cancer, no tumour responded despite lower IGF-1, and infusion-site abscesses were common.

?What side effects were seen?

Few in the bleeding studies, which reviews describe as minor. In volunteers it cut gallbladder emptying from about 60% to under 20%, and in the breast cancer trial continuous infusion under the skin caused abscesses in eight of 14 women and a small rise in blood glucose.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA via openFDA: search for generic name vapreotide returned no records. Read October 3, 2026.
  2. [clinical-trial] Calès P, et al. "Early administration of vapreotide for variceal bleeding in patients with cirrhosis." N Engl J Med, 2001;344(1):23-8. PMID: 11136956.
  3. [pubmed] Calès P. "Vapreotide acetate for the treatment of esophageal variceal bleeding." Expert Rev Gastroenterol Hepatol, 2008;2(2):185-92. PMID: 19072353.
  4. [pubmed] Fortune BE, et al. "Vapreotide: a somatostatin analog for the treatment of acute variceal bleeding." Expert Opin Pharmacother, 2009;10(14):2337-42. PMID: 19708854.
  5. [pubmed] "Vapreotide: BMY 41606, RC 160, Sanvar." Drugs R D, 2003;4(5):326-30. PMID: 12952505.
  6. [pubmed] Norman P. "Vapreotide (Debipharm)." IDrugs, 2000;3(11):1358-72. PMID: 16047258.
  7. [clinical-trial] Sarr MG. "The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial." J Am Coll Surg, 2003;196(4):556-64; discussion 564-5; author reply 565. PMID: 12691930.
  8. [clinical-trial] Ritz MA, et al. "The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects." Br J Clin Pharmacol, 1999;47(2):195-201. PMID: 10190655.
  9. [clinical-trial] Girard PM, et al. "Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases." AIDS, 1992;6(7):715-8. PMID: 1354449.
  10. [pubmed] González-Barcena D, et al. "Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse." Prostate, 2003;56(3):183-91. PMID: 12772187.
  11. [pubmed] O'Byrne KJ, et al. "Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer." Br J Cancer, 1999;79(9-10):1413-8. PMID: 10188884.
  12. [pubmed] Breeman WA, et al. "Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide." Eur J Nucl Med, 1998;25(2):182-6. PMID: 9473268.
  13. [pubmed] Veal N, et al. "Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis." Dig Dis Sci, 2003;48(1):154-61. PMID: 12645803.
  14. [pubmed] Spitsin S, et al. "Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor." Neuroimmunomodulation, 2013;20(5):247-55. PMID: 23921645.

Sources & Citations

Studies were read from their PubMed abstracts; no label exists. Read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03